✦ LIBER ✦

CA 19-9 as a prognostic index after resection for pancreatic cancer

✍ Scribed by Cosimo Sperti; Claudio Pasquali; Sandra Catalini; Francesco Cappellazzo; Bruno Bonadimani; Roubik Behboo; Dr. Sergio Pedrazzoli

Publisher: John Wiley and Sons
Year: 1993
Tongue: English
Weight: 485 KB
Volume: 52
Category: Article
ISSN: 0022-4790
DOI: 10.1002/jso.2930520302

No coin nor oath required. For personal study only.

✦ Synopsis

Serial serum CA 19-9 assays were performed in 30 consecutive patients who underwent resection for pancreatic cancer. Patients with preoperative CA 19-9 levels < 200 U/ml had significantly better prognosis than those with CA 19-9 > 200 Ulml ( P < 0.001). Serum tumor marker normalized in 14 patients after tumor resection, and survival in this group was significantly higher than that of patients with persistently elevated CA 19-9 ( P < 0.0001). Prognosis was also influenced by absence of lymph node metastases ( P < 0.02) and radicality of resection ( P < 0.005). Elevation of serum CA 19-9 levels after operation well predicted tumor recurrence from 1-10 months before clinical and radiological evidence. CA 19-9 determination is useful as a prognostic index after resection for pancreatic carcinoma and as a surveillance test in monitoring the efficacy of treatment.

📜 SIMILAR VOLUMES

Serum ca 50 as a tumor marker in pancrea

Serum ca 50 as a tumor marker in pancreatic cancer: A comparison with CA 19-9

✍ Caj Haglund; Pentti Kuusela; Hannu Jalanko; Peter J. Roberts 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 French ⚖ 459 KB

CA 50 is a new tumor marker based on a monoclonal anti-carcinoid tumor, 2 cystadenocarcinomas, 2 anaplastic carcibody (MAb) against a human colorectal carcinoma cell line.The nomas, 15 poorly differentiated and 39 well-to moderately-CA 50 antigen is similar, but not identical, to the tumor different

A new enzyme-linked lectin/mucin antibod

A new enzyme-linked lectin/mucin antibody sandwich assay (CAM 17.1/ WGA) assessed in combination with CA 19-9 and peanut lectin binding assay for the diagnosis of pancreatic cancer

✍ N. Parker; C. A. Makin; C. K. Ching; D. Eccleston; O. M. Taylor; D. Milton; Jona 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 621 KB

Background, Mucus glycoproteins are often present in the sera of patients with pancreatic cancer, and their detection and quantification can be used in serologic diagnosis. A novel enzyme-linked "sandwich" assay (CAM 17.1/WGA) has been developed in which a lectin, wheat germ agglutinin (WGA), is bo